The World Health Organization warned that artificial sweeteners, used to replace sugar in a vast range of products, do not help in losing weight and can have serious health effects.
According to the United Nations health agency, a systematic review of available evidence "suggests that use of non-sugar sweeteners (NSS) does not confer any long-term benefit in reducing body fat in adults or children.
In addition, results from the review suggest that the long-term use of NSS could increase the risk of type 2 diabetes, cardiovascular diseases, and mortality in adults.
The WHO's director for nutrition and food safety, Francesco Branca, stressed that replacing ordinary sugar with artificial sweeteners "does not help with weight control in the long term".
He added that NSS are not essential dietary factors and have no nutritional value.
The WHO said its new recommendation applied to everyone except individuals with pre-existing diabetes.
It includes all synthetic and naturally occurring or modified sweeteners not classified as sugars found in manufactured foods and beverages or sold on their own to be added to products by consumers.
Among the most widely used sweeteners are acesulfame K, aspartame, advantame, cyclamates, neotame, saccharin, sucralose, stevia, and stevia derivatives, it said.


U.S. Futures Steady as Rate-Cut Bets Rise on Soft Labor Data
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines
Microchip Technology Boosts Q3 Outlook on Strong Bookings Momentum
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
IMF Deputy Dan Katz Visits China as Key Economic Review Nears
Proxy Advisors Urge Vote Against ANZ’s Executive Pay Report Amid Scandal Fallout
Visa to Move European Headquarters to London’s Canary Wharf
Eli Lilly Becomes First Pharma Giant to Hit $1 Trillion Amid Soaring Weight-Loss Drug Demand
Netflix’s Bid for Warner Bros Discovery Aims to Cut Streaming Costs and Reshape the Industry
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand
Airline Loyalty Programs Face New Uncertainty as Visa–Mastercard Fee Settlement Evolves
Japan’s Nikkei Drops as Markets Await Key U.S. Inflation Data
BOJ Governor Ueda Highlights Uncertainty Over Future Interest Rate Hikes
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy
GM Issues Recall for 2026 Chevrolet Silverado Trucks Over Missing Owner Manuals 



